On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha), a biosimilar to Amgen’s NEUPOGEN (filgrastim). FILKRI was developed by Accord BioPharma, the U.S.
Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors This was an observational, noninferiority, cohort study of patients from ...
Clinical data from randomized studies demonstrated that Filkri is highly similar to the reference product with no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results